ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Please provide your email address to receive an email when new articles are posted on . Compared with a drug-eluting stent, patients who underwent PCI with a bioresorbable vascular scaffold had ...

A large network meta-analysis comparing numerous stent types across different clinical trials has shown that treatment with an everolimus-eluting bioresorbable vascular scaffold (BVS) is associated ...

For some, dissolving coronary stents represent one of the most promising technologies in interventional cardiology, but in recent months, multiple reports examining the performance of the leading ...

Please provide your email address to receive an email when new articles are posted on . “Drug-eluting stents reduce the rate of in-stent restenosis, myocardial infarction and target lesion ...

The initial results are in and it doesn’t look that great for vanishing or bioresorbable cardiac stents that are designed to dissolve into a patients’ body over time compared with durable drug-eluting ...

DENVER -- As new 3- and 4-year data emerged from the ABSORB clinical trials, the FDA updated its cautions to healthcare professionals about continuing risk seen with the first-generation Absorb ...

San Francisco — An everolimus-eluting stent with a resorbable scaffold showed superior efficacy in a randomized multicenter trial when compared with angioplasty for the treatment of patients with ...

Reva Medical has secured a CE mark for its drug-eluting bioresorbable coronary scaffold, Fantom. The regulatory green light sets Reva up to start competing with fellow bioresorbable stent pioneers ...

SAN DIEGO — Results from two randomized controlled trials of a bioresorbable vascular scaffold (BVS) that has been withdrawn from the market call into question the wisdom of continued development of ...